<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03733379</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE: 74049717.7.1001.5506</org_study_id>
    <nct_id>NCT03733379</nct_id>
  </id_info>
  <brief_title>Systemic Probiotics in the Periodontal Treatment</brief_title>
  <official_title>Clinical, Microbiological and Immunological Evaluation of the Effects of Systemic Probiotics in the Periodontal Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belén Retamal-Valdes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guarulhos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this multicenter randomized clinical trial is to evaluate the clinical,
      microbiological and immunological effects of probiotics as an adjunct to Scaling and Root
      Planing alone or in combination with Metronidazole and Amoxicillin in the treatment of
      periodontitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The association of scaling and root planing (SRP) with systemic metronidazole (MTZ) and
      amoxicillin (AMX) has been advocated as one of the most promising therapeutic protocol for
      the treatment of advanced periodontitis, since the early 2000's. More recently, probiotics
      has also been suggested as a promising adjunctive treatment for periodontitis due to their
      antimicrobial and anti-inflammatory properties. Therefore, the aim of this study is to
      evaluate the clinical, microbiological and immunological effects of probiotics as an adjunct
      to SRP alone or in combination with MTZ and AMX in the treatment of periodontitis. In this
      randomized, double-blind, placebo-controlled trial, subjects with periodontitis will be
      randomly assigned to receive (i) SRP alone, or combined with: (ii) two probiotics lozenges a
      day for 90 days (Prob), (iii) 400 of MTZ, plus AMX (500 mg) thrice a day (TID) for 14 days
      (MTZ+AMX), or (iv) Prob and MTZ+AMX. Subjects will be monitored up to 1 year post-therapy.
      Nine subgingival plaque samples will be collected at baseline and at 3, 6 and 12 months
      post-therapy; three samples in each of the following pockets categories: shallow (probing
      depth [PD]≤3 mm), moderate (PD=4-6 mm) and deep (PD≥7 mm). The microbiological samples will
      be analyzed by checkerboard DNA-DNA hybridization for 40 bacterial species. Two
      non-contiguous diseased sites (i.e PD and CAL ≥ 5mm, bleeding and probing [BOP] and no
      furcation involvement) and two non-contiguous healthy sites (i.e. PD and clinical attachment
      level [CAL] ≤ 4 mm without BoP and/or marginal bleeding) will be randomly chosen per patient
      for gingival crevicular fluid (GCF) sampling, from the same sites selected for the
      microbiological monitoring. Peripheral blood samples will also be collected one week after
      clinical examination. The GCF and blood samples will be analyzed using a multi-analyte method
      by means of a 17-multiplex fluorescent bead-based immunoassay for 17 cyto/chemokines. The
      significance of differences over the course of the study will be sought using repeated
      measures ANOVA and Tukey multiple comparison tests, and at each time point (among groups)
      using either ANOVA and Tukey multiple comparison tests or ANCOVA with adjustments for the
      baseline values. The Chi-square test will be used to compare the differences in the frequency
      of gender, and to compare the differences in the frequency of subjects achieving the clinical
      endpoint at 1 year and of self-perceived adverse effects. A stepwise forward logistic
      regression analysis will be performed in order to investigate the impact of predictor
      variables on the clinical endpoint for treatment, i.e., &quot;presence of ≤4 sites with PD≥5 mm at
      12 months post-therapy (yes/no)&quot;. The Number Needed to Treat (NNT) with adjunctive antibiotic
      in order to obtain treatment success (≤4 sites with PD ≥5 mm) will be calculated. The level
      of significance will be set at 5%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects reaching ≤ 4 periodontal sites with probing depth (PD) ≥ 5 mm at 12 months</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of sites with PD ≥ 5 mm.</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sites with PD ≥ 6 mm.</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sites with PD ≥ 7 mm.</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of sites with PD ≥ 5 mm.</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of sites with PD ≥ 6 mm</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the number of sites with PD ≥ 7 mm</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PD changes in sites with initial PD between 4-6 mm</measure>
    <time_frame>Baseline - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PD changes in sites with initial PD ≥ 7 mm.</measure>
    <time_frame>Baseline - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean CAL changes in sites with initial CAL between 4-6 mm</measure>
    <time_frame>Baseline - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean CAL changes in sites with initial CAL ≥ 7 mm.</measure>
    <time_frame>Baseline - 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-mouth Probing Depth (mm).</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Full-mouth Clinical Attachment Level (mm)</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of sites with bleeding on probing</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of sites with plaque accumulation</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of sites with marginal bleeding</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of headache obtained through a questionnaire of adverse effects</measure>
    <time_frame>14 days after taking antibiotic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of headache obtained through a questionnaire of adverse effects</measure>
    <time_frame>90 days after taking probiotic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of vomiting obtained through a questionnaire of adverse effects</measure>
    <time_frame>14 days after taking antibiotic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of vomiting obtained through a questionnaire of adverse effects</measure>
    <time_frame>90 days after taking probiotic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of diarrhea obtained through a questionnaire of adverse effects.</measure>
    <time_frame>14 days after taking antibiotic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of diarrhea obtained through a questionnaire of adverse effects.</measure>
    <time_frame>90 days after taking probiotic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of nausea obtained through a questionnaire of adverse effects.</measure>
    <time_frame>14 days after taking antibiotic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of nausea obtained through a questionnaire of adverse effects.</measure>
    <time_frame>90 days after taking probiotic</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of periodontal pathogenic bacterial species.</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Counts of periodontal pathogenic bacterial species.</measure>
    <time_frame>Baseline, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Counts of chemokines in the crevicular gingival fluid.</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Counts of chemokines in the peripheral blood samples</measure>
    <time_frame>Baseline and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Periodontitis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scaling and root planing + Placebos of Metronidazole and Amoxicillin three times a day (TID) for 14 days + lozenges of probiotics two times a day for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + placebo lozenges of probiotics two times a day for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic + probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Scaling and root planing + Metronidazole (400 mg/thrice a day,TID) and Amoxicillin (500 mg/ TID) for 14 days + lozenges of probiotics two times a day for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Scaling and root planing</intervention_name>
    <description>SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.</description>
    <arm_group_label>Antibiotic</arm_group_label>
    <arm_group_label>Antibiotic + probiotic</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>SRP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole and Amoxicillin placebos</intervention_name>
    <description>Amoxicillin and metronidazole placebos thrice a day for 14 days (beginning with the first SRP session).</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 400 mg thrice a day for 14 days (beginning with the first SRP session).</description>
    <arm_group_label>Antibiotic</arm_group_label>
    <arm_group_label>Antibiotic + probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Amoxicillin 500 mg thrice a day for 14 days (beginning with the first SRP session).</description>
    <arm_group_label>Antibiotic</arm_group_label>
    <arm_group_label>Antibiotic + probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>The probiotic contains 2 different strains of Lactobacillus reuteri: L.reuteri DSM 17938 and L. reuteri ATCC PTA 5289 each at a concentration of 1 x 108 CFU per tablet. It will be used 2 times per day by 90 days.</description>
    <arm_group_label>Probiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic placebo</intervention_name>
    <description>The placebo is identical to the active but without L. reuteri. The two Study Products are identical in taste, texture and shape. It will be used 2 times per day by 90 days.</description>
    <arm_group_label>Antibiotic + probiotic</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥30 years of age;

          -  at least 15 teeth (excluding third molars and teeth with advanced decay indicated for
             extraction);

          -  a minimum of 6 teeth with at least one site each with probing depth (PD) and clinical
             attachment level (CAL) ≥5 mm;

          -  at least 30% of the sites with probing depth (PD) and clinical attachment level (CAL)
             ≥4 mm and bleeding on probing (BOP);

        Exclusion Criteria:

          -  pregnancy;

          -  breastfeeding;

          -  current smoking and former smoking within the past 5 years;

          -  systemic diseases that could affect the progression of periodontitis (e.g. diabetes,
             immunological disorders, osteoporosis);

          -  scaling and root planing an in the previous 12 months;

          -  antibiotic therapy in the previous 6 months;

          -  long-term intake of anti-inflammatory medications;

          -  need for antibiotic pre-medication for routine dental therapy;

          -  use of orthodontic appliances;

          -  extensive dental prosthetic rehabilitation;

          -  allergy to metronidazole and/or amoxicillin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Magda Feres, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Guarulhos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Belén Retamal-Valdes, Professor</last_name>
    <phone>+55 (11) 942801064</phone>
    <email>belenretamalvaldes@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Magda Feres, Professor</last_name>
    <email>mferes@ung.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal University of Paraná</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80210170</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geisla Soares, Professor</last_name>
      <phone>+55 (41) 33604134</phone>
      <email>geisla.soares@ufpr.br</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Temporão, Master student</last_name>
      <phone>+55 (41) 99960339</phone>
      <email>natalie.temporao@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Guarulhos</name>
      <address>
        <city>Guarulhos</city>
        <state>São Paulo</state>
        <zip>07023-070</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Belén Retamal-Valdes, Professor</last_name>
      <phone>+55 (11) 942801064</phone>
      <email>belenretamalvaldes@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Magda Feres, Professor</last_name>
      <email>mferes@ung.br</email>
    </contact_backup>
    <investigator>
      <last_name>Luciene Figueiredo, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marcelo Faveri, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Poliana Duarte, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Feres M, Figueiredo LC, Soares GM, Faveri M. Systemic antibiotics in the treatment of periodontitis. Periodontol 2000. 2015 Feb;67(1):131-86. doi: 10.1111/prd.12075. Review.</citation>
    <PMID>25494600</PMID>
  </reference>
  <results_reference>
    <citation>Feres M, Soares GM, Mendes JA, Silva MP, Faveri M, Teles R, Socransky SS, Figueiredo LC. Metronidazole alone or with amoxicillin as adjuncts to non-surgical treatment of chronic periodontitis: a 1-year double-blinded, placebo-controlled, randomized clinical trial. J Clin Periodontol. 2012 Dec;39(12):1149-58. doi: 10.1111/jcpe.12004. Epub 2012 Sep 27.</citation>
    <PMID>23016867</PMID>
  </results_reference>
  <results_reference>
    <citation>Borges I, Faveri M, Figueiredo LC, Duarte PM, Retamal-Valdes B, Montenegro SCL, Feres M. Different antibiotic protocols in the treatment of severe chronic periodontitis: A 1-year randomized trial. J Clin Periodontol. 2017 Aug;44(8):822-832. doi: 10.1111/jcpe.12721. Epub 2017 Jul 26.</citation>
    <PMID>28303587</PMID>
  </results_reference>
  <results_reference>
    <citation>Laleman I, Yilmaz E, Ozcelik O, Haytac C, Pauwels M, Herrero ER, Slomka V, Quirynen M, Alkaya B, Teughels W. The effect of a streptococci containing probiotic in periodontal therapy: a randomized controlled trial. J Clin Periodontol. 2015 Nov;42(11):1032-41. doi: 10.1111/jcpe.12464. Epub 2015 Nov 29.</citation>
    <PMID>26427036</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Guarulhos</investigator_affiliation>
    <investigator_full_name>Belén Retamal-Valdes</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Periodontitis</keyword>
  <keyword>Probiotic</keyword>
  <keyword>Metronidazole</keyword>
  <keyword>Amoxicillin</keyword>
  <keyword>Scaling and root planing</keyword>
  <keyword>Periodontal treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periodontitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

